Core Viewpoint - Company Kubo Medical-B (02216) announced the acquisition of 157,800 shares of Series B preferred stock in Valgen Holding Corporation for a total consideration of $15 million, representing 1.05% of the target company's fully diluted and converted shares outstanding as of the announcement date [1] Group 1: Acquisition Details - The acquisition is being made by Broncus China Holding Corporation, a wholly-owned subsidiary of Kubo Medical-B [1] - Valgen Holding Corporation primarily provides systemic solutions for diseases such as mitral regurgitation and tricuspid regurgitation [1] - The products of Valgen include the DragonFly mitral valve repair device (via the transvenous approach) and the DragonFly-TTM tricuspid valve repair device [1] Group 2: Strategic Rationale - The board believes that the acquisition presents a valuable opportunity for the company to achieve comprehensive diagnosis and treatment of cardiopulmonary diseases, given the similarities and correlations between structural heart diseases and pulmonary diseases [1] - The collaboration with Valgen will leverage the company's expertise in chronic obstructive pulmonary disease to establish a solid foundation for a comprehensive cardiopulmonary diagnosis and treatment platform [1] - The acquisition also provides an opportunity to enhance the company's R&D capabilities, applying structural heart disease treatment technologies to pulmonary disease treatments and vice versa [1]
堃博医疗-B拟1500万美元收购Valgen Holding Corporation15.78万股B系列优先股